Human EGFRvIII chimeric antigen receptor T cells demonstrate favorable safety profile and curative responses in orthotopic glioblastoma.
Rebecca C AbbottMelinda IliopoulosKatherine A WatsonValeria ArcucciMargareta GoHannah E Hughes-ParryPete SmithMelissa J CallRyan S CrossMisty R JenkinsPublished in: Clinical & translational immunology (2023)
This study demonstrates the preclinical functionality of a highly specific CAR targeting EGFRvIII on human cells. This CAR could be an effective treatment for glioblastoma and warrants future clinical investigation.